Response to Government granting faster access to cannabis-based medicines

2 March 2020, London: EMMAC Life Sciences Group, Europe’s leading independent cannabis company welcomes the decision made earlier today by the UK Government to change import restrictions on medicinal cannabis products, which will provide faster access to cannabis-based products for medicinal use resulting in UK patients not have their treatment delayed or interrupted.

EMMAC’s vertically integrated supply chain and distribution network across Europe ensures that high quality medical cannabis products meet growing patient demand. EMMAC believes that Rokshaw Laboratories, its wholly owned UK manufacturer of specials with licenses to import, manufacture and securely deliver medical cannabis products (‘CBPMs’) direct to UK-based patients through its onsite distance pharmacy, is well placed to provide patients with “quick and uninterrupted access to cannabis-medicinal products” identified as important considerations in today’s announcement by the UK Government. (

Antonio Costanzo, CEO of EMMAC, commented: “This is a significant milestone for the cannabis sector in the UK as well as for EMMAC, as Europe’s leading medical cannabis company. Following today’s announcement, patients in the UK will have quicker and more reliable access to medical cannabis. We believe this will have a significant impact on the sector by reducing costs and leading to further clinical research. EMMAC is leading the way in providing patients with the highest quality medical cannabis and we welcome the UK Government’s decision made today.”

About EMMAC Life Sciences Group

EMMAC Life Sciences Group is Europe’s leading independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it.

For scientific enquiries please contact
For general enquiries please contact or visit

Media enquiries:
Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz Tel: +44 (0) 20 7466 5000


All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.